A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Tran, B. [1 ]
Kouros-Mehr, H. [2 ]
Fermin, A. [2 ]
Horvath, L. [3 ]
Roncolato, F. [4 ]
Rettig, M. [5 ]
Dorff, T. [6 ]
Tagawa, S. T. [7 ]
Subudhi, S. K. [8 ]
Antonarakis, E. S. [9 ]
Armstrong, A. J. [10 ]
Petrylak, D. P. [11 ]
Fizazi, K. [12 ]
Salvati, M. E. [2 ]
Scher, H. I. [13 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Amgen Inc, Early Dev Oncol, Thousand Oaks, CA 91320 USA
[3] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia
[4] Scientia Clin Res Ltd, Nelune Comprehens Canc Ctr, Randwick, NSW, Australia
[5] Univ Calif Los Angeles, Dept Med & Urol, Los Angeles, CA USA
[6] City Hope Natl Med Ctr, Dept Med Oncol & Dev Therapeut, 1500 E Duarte Rd, Duarte, CA 91010 USA
[7] Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[9] Johns Hopkins Univ, Dept Med Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[10] Duke Univ, Dept Med, Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA
[11] Yale Canc Ctr, Dept Med Oncol, New Haven, CT USA
[12] Gustave Roussy Canc Ctr, Canc Med, Villefranche Sur Mer, France
[13] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
895TiP
引用
收藏
页码：353 / 353
页数：1
相关论文
共 50 条
  • [1] Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Tran, Ben
    Horvath, Lisa
    Dorff, Tanya B.
    Greil, Richard
    Machiels, Jean-Pascal H.
    Roncolato, Felicia
    Autio, Karen A.
    Rettig, Matthew
    Fizazi, Karim
    Lolkema, Martijn P.
    Fermin, Anthony C.
    Salvati, Mark
    Kouros-Mehr, Hosein
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
    Tran, B.
    Horvath, L.
    Dorff, T.
    Rettig, M.
    Lolkema, M. P.
    Machiels, J-P.
    Rottey, S.
    Autio, K.
    Greil, R.
    Adra, N.
    Lemech, C.
    Minocha, M.
    Cheng, F-C.
    Kouros-Mehr, H.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S507 - S507
  • [3] Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Ben Tran
    Horvath, Lisa
    Rettig, Matthew
    Fizazi, Karim
    Lolkema, Martijn P.
    Dorff, Tanya B.
    Greil, Richard
    Machiels, Jean-Pascal H.
    Autio, Karen A.
    Rottey, Sylvie
    Adra, Nabil
    Garje, Rohan
    Roncolato, Felicia
    Tagawa, Scott T.
    Shariat, Shahrokh F.
    Salvati, Mark
    Poon, Shirley
    Kouros-Mehr, Hosein
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] PHASE 1 STUDY OF AMG 160, A HALF-LIFE EXTENDED BITE® (BISPECIFIC T-CELL ENGAGER) THERAPY TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Dorff, Tanya
    Rettig, Matthew
    Machiels, Jean-Pascal
    Lolkema, Martijn
    Autio, Karen
    Greil, Richard
    Rottey, Sylvie
    Adra, Nabil
    Salvati, Mark
    Poon, Shirley
    Tan, Daniel
    Jurida, Gabor
    Kouros-Mehr, Hosein
    Fizazi, Karim
    Tran, Ben
    Horvath, Lisa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A207 - A208
  • [5] A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
    Dorff, Tanya
    Horvath, Lisa G.
    Autio, Karen
    Bernard-Tessier, Alice
    Rettig, Matthew B.
    Machiels, Jean-Pascal
    Bilen, Mehmet A.
    Lolkema, Martijn P.
    Adra, Nabil
    Rottey, Sylvie
    Greil, Richard
    Matsubara, Nobuaki
    Tan, Daniel S. W.
    Wong, Alvin
    Uemura, Hiroji
    Lemech, Charlotte
    Meran, Johannes
    Yu, Youfei
    Minocha, Mukul
    Mccomb, Mason
    Penny, Hweixian Leong
    Gupta, Vinita
    Hu, Xuguang
    Jurida, Gabor
    Kouros-Mehr, Hosein
    Janat-Amsbury, Margit M.
    Eggert, Tobias
    Tran, Ben
    CLINICAL CANCER RESEARCH, 2024, 30 (08) : 1488 - 1500
  • [6] Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
    Hummel, Horst-Dieter
    Kufer, Peter
    Grullich, Carsten
    Deschler-Baier, Barbara
    Chatterjee, Manik
    Goebeler, Maria-Elisabeth
    Miller, Kurt
    De Santis, Maria
    Loidl, Wolfgang C.
    Buck, Andreas
    Wittemer-Rump, Sabine
    Koca, Goekben
    Boix, Oliver
    Doecke, Wolf-Dietrich
    Stienen, Sabine
    Sayehli, Cyrus
    Bargou, Ralf C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).
    Subudhi, Sumit Kumar
    Siddiqui, Bilal A.
    Maly, Joseph J.
    Nandagopal, Lakshminarayanan
    Lam, Elaine Tat
    Whang, Young E.
    Minocha, Mukul
    Gupta, Vinita
    Penny, Xianne
    Cooner, Freda
    Jhones, Camila
    Paluch, Andrew
    Salvati, Mark
    Janat-Amsbury, Margit
    Eggert, Tobias
    Kouros-Mehr, Hosein
    Joshua, Anthony M.
    Aggarwal, Rahul Raj
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC).
    Bailis, Julie
    Deegen, Petra
    Thomas, Oliver
    Bogner, Pamela
    Wahl, Joachim
    Liao, Mike
    Li, Shyun
    Matthes, Katja
    Naegele, Virginie
    Rau, Doris
    Rattel, Benno
    Raum, Tobias
    Kufer, Peter
    Coxon, Angela
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
    Deegen, Petra
    Thomas, Oliver
    Nolan-Stevaux, Olivier
    Li, Shyun
    Wahl, Joachim
    Bogner, Pamela
    Aeffner, Famke
    Friedrich, Matthias
    Liao, Michael Z.
    Matthes, Katja
    Rau, Doris
    Rattel, Benno
    Raum, Tobias
    Kufer, Peter
    Coxon, Angela
    Bailis, Julie M.
    CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2928 - 2937
  • [10] Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
    Hummel, Horst-Dieter
    Kufer, Peter
    Gruellich, Carsten
    Deschler-Baier, Barbara
    Chatterjee, Manik
    Goebeler, Maria-Elisabeth
    Miller, Kurt
    De Santis, Maria
    Loidl, Wolfgang C.
    Buck, Andreas
    Wittemer-Rump, Sabine
    Koca, Goekben
    Boix, Oliver
    Doecke, Wolf-Dietrich
    Stienen, Sabine
    Sayehli, Cyrus
    Bargou, Ralf C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345